Article Date: 20 Aug 2013 - 0:00 PDT Current ratings for:
Metal-catalyzed cross-couplings of carbon bonds could enable creation of libraries of drug candidates to accelerate drug discovery
James Bond had his reasons for ordering his martinis "shaken, not stirred." Similarly, drug manufacturers need to make sure the molecules in a new drug are arranged in an exact manner, lest there be dire consequences. Specifically, they need to be wary of enantiomers, mirror-image molecules composed of the same atoms, but arranged differently.
"One mirror image could be therapeutic while another could be poisonous," said Dr. Mark R. Biscoe, assistant professor of chemistry at The City College of New York. The classic case is thalidomide, a drug marketed in the 1950s and 1960s to treat morning sickness, which resulted in serious birth defects.
Professor Biscoe led a team of researchers at CCNY that developed a new method for preparing libraries of single-enantiomer molecules for therapeutic and toxicity studies that is faster and potentially less costly than methods now used in the pharmaceutical industry. Their findings were reported in Nature Chemistry.
Currently, drug developers typically rely on a chiral resolution process whereby compounds with roughly equal parts of the two enantiomers are separated into the individual enantiomers. Bioenzymatic processes can also be employed to generate single-enantiomer molecules. These strategies are wasteful and costly, Professor Biscoe explained.
He and colleagues found that a metal such as palladium could be employed to achieve a cross-coupling reaction with a single-enantiomer molecule without impacting the integrity of the mirror image formed in the product. By doing so, they could isolate one mirror image for evaluation as a drug candidate.
"By using a single-enantiomer partner in a cross-coupling reaction, we can rapidly generate a diverse library of biologically active molecules for use in drug screening," he said.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.Visit our pharma industry / biotech industry section for the latest news on this subject.
The research was funded by the National Institutes of Health, City College, the Alfred P. Sloan Foundation and PSC-CUNY, with additional support from the National Science Foundation and the American Chemical Society Petroleum Research Fund.
Stereoretentive Pd-catalysed Stille cross-coupling reactions of secondary alkyl azastannatranes and aryl halides
Ling Li, Chao-Yuan Wang, Rongcai Huang & Mark R. Biscoe; Nature Chemistry 5, 607–612 (2013) doi:10.1038/nchem.1652
City College of New York
Please use one of the following formats to cite this article in your essay, paper or report:MLA
20 Aug. 2013.
City College of New York. (2013, August 20). "Metal-catalyzed cross-couplings of carbon bonds could enable creation of libraries of drug candidates to accelerate drug discovery." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/264981.php.
Please note: If no author information is provided, the source is cited instead.
'Metal-catalyzed cross-couplings of carbon bonds could enable creation of libraries of drug candidates to accelerate drug discovery'
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
